From: Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigation
HR (95% CI)
P-value
Drug type
ICPi
ref.
Other anticancer drugs
1.1 (0.8–1.7)
0.55
Study phase
Phase 1
Phase 2 or 3
1.7 (1.1–2.6)
0.02
Multi-country study
No
Yes
1 (0.4–2.2)
0.95
Sample size
Smaller
Larger
1.4 (0.8–2.2)
0.16